Attached files

file filename
EX-31.2 - EX-31.2 - Fortress Biotech, Inc.d581596dex312.htm
EX-31.1 - EX-31.1 - Fortress Biotech, Inc.d581596dex311.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-Q/A

(Amendment No. 1)

 

 

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2013

OR

 

¨ TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934

From the transition period from                      to                     .

Commission File Number 001-35366

 

 

CORONADO BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   20-5157386

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

24 New England Executive Park

Burlington, MA 01803

(Address of principal executive offices)

(781) 652-4500

(Issuer’s telephone number)

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer   ¨    Accelerated filer   x
Non-accelerated filer   ¨  (Do not check if a smaller reporting company)    Smaller reporting company   ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x

As of August 2, 2013, there were 31,901,334 shares of Common Stock of the issuer outstanding.

 

 

 


EXPLANATORY NOTE

This Form 10-Q/A (Amendment No. 1) hereby amends the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2013, filed with the Securities and Exchange Commission (the “SEC”) on August 5, 2013 (“Form 10-Q”). This Amendment is being filed solely to correct the inadvertent omission of certain language provided in Exhibits 31.1 and 31.2 to the Form 10-Q.

This Amendment does not reflect events after the date of filing of the Form 10-Q and does not modify or update disclosures made in the Form 10-Q except to correct the language in Exhibits 31.1 and 31.2. Accordingly, this Amendment should be read in conjunction with the Form 10-Q and the Registrant’s filings made with the SEC subsequent to the date of filing of the Form 10-Q.


Item 6. Exhibits.

(b) Exhibits

The following exhibits are filed with this Amendment:

 

Exhibit
No.

  

Description

31.1    Certification of Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2    Certification of Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

        CORONADO BIOSCIENCES, INC.
Date: August 12, 2013     By:  

/s/ Harlan F. Weisman

      Harlan F. Weisman, Chief Executive Officer (Principal Executive Officer)
Date: August 12, 2013     By:  

/s/ Lucy Lu, M.D.

      Lucy Lu, M.D., Executive Vice President and Chief Financial Officer (Principal Financial Officer)
Date: August 12, 2013     By:  

/s/ Dale Ritter

      Dale Ritter, Senior Vice President, Finance and Chief Accounting Officer (Principal Accounting Officer)

 

3


EXHIBIT INDEX

 

Exhibit

No.

  

Description

  31.1    Certification of Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
  31.2    Certification of Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

4